Orphan Drug, Domestic Developers Shine In China Annual Approvals Tally
Half Of Priority Reviews For Homegrown Firms
10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.
